‘The Retrievals' is not meant to scare you
Hi Retrievals listeners,
Episode 2 drops today!
If you missed the Episode 1 newsletter, about what led me to report on the problem of severe pain during C-sections and the people trying to solve it, you can find it here.
Episode 2 takes up the question of 'why?' Why are patients feeling everything during C-sections? It's not an easy question to answer, and in this episode, we hear what happens when a doctor gets up onstage and asks a ballroom full of anesthesiologists to wrestle with it.
Last week, when we announced the new season on Instagram, hundreds of readers responded in the comments, often with personal stories of painful C-sections. Others questioned whether it was even a good idea to put this type of content out there on Instagram.
Personally what I find scary is that 100,000 U.S. patients a year are feeling significant pain during major abdominal surgery and that hardly anyone knows about it. Yes, it would be great if everyone could have a one-on-one consultation with an anesthesiologist before they even go into labor. It's not such a pie-in-the-sky idea: People are thinking about how to make this a reality. (Search this report for 'prenatal anesthesia consultations.') But right now that's not how our system works.
So now that you know that this can happen during a C-section, what do you do with that information?
Often the answer to this question is: Advocate for yourself! And, yes, but that should not be the only answer. The responsibility should not be on patients to fix this problem. Yesterday a listener sent me an email saying that when the doctors tested her spinal block before her C-section, she could tell the block wasn't working. Initially she was met with disbelief, and so, lying exposed on the operating table she had to, she wrote, 'project manage' the OR in order to get the care she needed. You should not have to project manage your own C-section.
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Vionic Names Gabby Reece as First-Ever Well-Being Ambassador
The iconic athlete and wellness leader joins forces with the science-based footwear brand to redefine wellbeing from the ground up. ST. LOUIS, August 05, 2025--(BUSINESS WIRE)--Vionic, the footwear brand rooted in biomechanics and the science of movement and a lead brand in the Caleres (NYSE: CAL) portfolio, introduces its first-ever well-being ambassador: Gabby Reece. A world-class athlete and wellness advocate, she believes everyone is an athlete, not by physical definition but by mindset. In this role, Reece brings her philosophy centered around movement as the vital tool for wellbeing to Vionic. She is featured in the brand's fall campaign and content vehicles. The partnership underscores Vionic's commitment and distinction in creating footwear equally rooted in science and style. "Vionic has tremendous long-term potential, unique authority in science-backed movement and an unwavering commitment to innovation. As we honor and build upon the Vionic brand heritage, we look to deepen its distinction and expand its relevance in ways that are both authentic and hard to replicate," said Jay Schmidt, president and chief executive officer of Caleres. "Vionic's partnership with Gabby Reece illustrates our lead brand strategy in action and reflects our focus on long-term brand-building that drives value over time." A beach volleyball legend, bestselling author, podcast host, and co-founder of Laird Superfood, Reece brings a lifelong dedication to movement, balance, and high-performance living to her role as Vionic's ambassador. She personifies the brand's core values of strength, resilience, innovation and its belief that wellbeing starts with movement. "I believe what you put on your feet in the morning matters. This isn't just a collaboration - it's a commitment to redefining well-being from the ground up," said Reece. "Vionic understands that function is not a compromise - it's the foundation. When paired with thoughtful, beautiful design, that's when it truly works. I've worn Vionic shoes for years, so joining the brand in a meaningful way feels like a natural fit." As part of her ambassador role, Reece will create engaging content, lead conversations around well-being, and collaborate with the Vionic team to design the brand's most high-performance and technologically advanced walking shoe to date. Reece made history as the first female athlete to design a shoe for Nike. From that iconic partnership to this one, Reece understands the importance of form and function, a common theme throughout her life. The design of the sneaker captures Reece's belief in strength and grace in equal measure and a reflection of a commitment to show up for yourself every day. The sneaker is slated to launch in Spring 2026. Follow along and learn more at and on social at @VionicShoes. About Vionic Shoes: Vionic designs its VIO-MOTION technology into every shoe it makes, resulting in unparalleled stability, ultimate arch support, and cushioning. As pioneers in foot health with a global team of experts behind the brand, Vionic brings a fresh perspective to fashionable, supportive footwear. Featuring a wide range of silhouettes, premium materials, and thoughtful design for women and men, Vionic offers the style you want with the comfort you crave across a vast selection of active, casual & dress options, sandals, and slippers. Press features for Vionic include the cover of O, The Oprah Magazine, as well as coverage in InStyle, Women's Health, Buzzfeed, Refinery29, Men's Health, Travel + Leisure, People, and on The Today Show. For additional information about Vionic footwear, visit About Caleres: Caleres is a market-leading portfolio of global footwear brands that includes Famous Footwear, Sam Edelman, Allen Edmonds, Naturalizer, Vionic and more. Our products are available virtually everywhere - in the nearly 1,000 retail stores we operate, in hundreds of major department and specialty stores, on our branded e-commerce sites, and on many additional third-party retail platforms. Combined, these brands make Caleres a company with both a legacy and a mission. Our legacy is nearly 150 years of craftsmanship and our passion for fit, while our mission is to continue to inspire people to feel great…feet first. Visit to learn more about us. About Gabby Reece: Gabby Reece is a volleyball legend, inspirational leader, and trailblazer in health and fitness. She's a New York Times bestselling author, devoted wife and mother, and a powerful voice in the wellness space. As host of The Gabby Reece Show, a top-rated podcast, she interviews leading experts in health, wellness, sports, psychology and business to deliver valuable, actionable insights to her audience. Reece is also the Co-Founder of XPT (Extreme Performance Training™) and Laird Superfood, continuing her mission to lead and innovate within the health and fitness industry. View source version on Contacts Media Contact:Anna Claytonanna@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Hims & Hers stock slides 5% after second quarter revenue misses forecasts
Hims & Hers Health (HIMS) stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of Wall Street forecasts while maintaining its full-year forecast. The telehealth company posted revenue of $544.8 million in the second quarter, which marked a 73% increase year-over-year but missed analyst estimates for $552 million, according to Bloomberg data. Hims maintained its full-year revenue guidance of $2.3 billion-$2.4 billion. Earnings per share topped forecasts, coming in at $0.17 against expectations for $0.15. The stock had dropped as much as 11% in premarket trade. Hims' slide comes after drugmaker Novo Nordisk (NVO) ended a short-lived partnership between the two companies in June that saw Novo Nordisk allows Hims access to its viral weight-loss drug Wegovy. Novo Nordisk alleged in the announcement that Hims "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of "personalization" and are disseminating deceptive marketing that put patient safety at risk." Shares in Novo Nordisk fell more than 21% last month after the drugmaker announced that it was slashing profit forecasts for Wegovy and its diabetes treatment Ozempic. In August 2022, the US Federal Drug Administration (FDA) allowed compounding pharmacies, including those working with telehealth providers like Hims, to copy and distribute semaglutide weight-loss and weight-management drugs due to shortages in brand-name products like Wegovy and Eli Lilly's (LLY) Zepbound after massive consumer demand. The move allowed Hims to market a GLP-1 weight-loss drug itself while the shortage was in place, which it began doing in May 2024, according to the FT. But the FDA ended that order in February, citing that the shortage of brand-name GLP-1s had ended and ordering compounding pharmacies to stop production by April. Coming off the FDA ruling, Hims is trying to diversify its product offerings. Management announced in May in a Q1 shareholder letter that its "vision involves expanding from hundreds of personalized treatments today to potentially thousands." Still, the company's stock has been a big winner relative to GLP-1 leaders like Novo and Eli Lilly this year, rising more than 150% year-to-date against a more than 40% slide for Novo shares. Eli Lilly stock is roughly flat this year. "The momentum we saw through the first half of 2025 is proof that our platform is delivering exactly what millions of people have been waiting for, access to personalized, high-quality care that meets people where they are," CEO Andrew Dudum said during Hims' Q2 earnings call. "From the beginning, we have believed that medicine should be centered on the individual, not the system. We are now seeing the market demanding just that. What we have built is working and it's working at scale." Jake Conley is a breaking news reporter covering US equities for Yahoo Finance. Follow him on X at @byjakeconley or email him at Sign in to access your portfolio
Yahoo
30 minutes ago
- Yahoo
Topical Drug Delivery Market US$409.0 Billion Forecast by 2030 with 8.8% CAGR
DELRAY BEACH, Fla., Aug 5, 2025 /PRNewswire/ -- The global Topical Drug Delivery Market, valued at US$247.3 billion in 2024 stood at US$268.4 billion in 2025 and is projected to advance at a resilient CAGR of 8.8% from 2025 to 2030, culminating in a forecasted valuation of US$409.0 billion by the end of the period. The growth of the topical drug delivery market can be primarily attributed to factors such as the high prevalence of skin infections, increasing investments in pharmaceutical R&D, the growing emphasis on patient convenience, the high incidence of burn injuries, and the increasing prevalence of chronic diseases. The opportunities for market growth include the growing preference for self-administration, particularly for chronic skin conditions and pain management. Products like transdermal patches, medicated creams, and gels enable patients to manage treatment conveniently at home, reducing their dependence on clinical visits. Download PDF Brochure: Browse in-depth TOC on "Topical Drug Delivery Market" 468 - Tables71 - Figures435 - Pages By product, the topical drug delivery market is segmented into semi-solid formulations, liquid formulations, solid formulations, transdermal products, and other products. Other products include stick, aerosol (spray), and foam. The large share of the semi-solid formulations segment is attributed to its convenience and ease of application, limited side effects that improve patient adherence, and the ability to topically deliver a wide variety of drug molecules compared to other formulations. By application, the market is segmented into dermal drug delivery, ophthalmic drug delivery, rectal drug delivery, vaginal drug delivery, and nasal drug delivery. In 2024, the dermal drug delivery segment accounted for the largest share of the market. The large share of this segment is attributed to the several key advantages offered, such as the ease of use and increased patient compliance for long-term treatment in conditions for chronic pain or skin disorders. Dermal drugs also have fewer regulatory requirements than ophthalmic products, which leads to increasingly accessible product launches and broad adoption. By end user, the market is segmented into home care settings, ambulatory surgery centers, hospitals & clinics, burn care centres, and other end users. The home care settings segment accounted for the largest share of the market in 2024. Topical drug delivery systems are increasingly gaining prominence, not just as an alternative route of drug delivery but also as point-of-care devices in home care settings. The market's growth is primarily attributed to improved patient accessibility owing to high awareness and comfort. By geography, in 2024, North America accounted for the largest share of the topical drug delivery market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Market growth in this region is characterized by the availability of favorable reimbursement options, increasing awareness about novel pharmaceutical drug delivery technologies, the implementation of favorable government initiatives, growing affordability and per capita healthcare expenditure, and the presence of several global pharmaceutical giants. Request Sample Pages : The prominent players in the topical drug delivery market are Johnson & Johnson Services, Inc. (US), Galderma (Switzerland), Bayer AG (Germany), Novartis AG (Switzerland), AbbVie Inc. (US), GSK Plc. (UK), Bausch Health Companies Inc. (Canada), Glenmark Pharmaceuticals Limited (India), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Boehringer Ingelheim International GmbH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Viatris Inc. (US), Organon group of companies (US), , Solventum (US), Crescita Therpeautics Inc. (Canada), Luye Pharma Group (China), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Rusan Pharma Ltd. (India) and AdhexPharma (France). Johnson & Johnson Private Limited (US): The company primarily focuses on human health and well-being. J&J operates through two business segments: Innovative Medicine and MedTech. Topical drug delivery products fall under the Innovative Medicine segment, which is focused on six therapeutic areas: Immunology (e.g., rheumatoid arthritis, inflammatory bowel disease, and psoriasis), Infectious Diseases (e.g., HIV/AIDS), Neuroscience (e.g., mood disorders, neurodegenerative disorders, and schizophrenia), Oncology (e.g., prostate cancer and hematologic malignancies), Cardiovascular and Metabolism (e.g., thrombosis and diabetes), and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension). The company has a strong presence across North America, Europe, the Asia Pacific, and Africa. Galderma (Switzerland) Galderma offers premium brands and services across injectable aesthetics, dermatological skincare, and therapeutic dermatology. The company provides topical products under all three segments. Injectable Aesthetics consists of hyaluronic acid (HA) fillers and botulinum neuromodulators. Dermatological skincare consists of consumer care brands such as Cetaphil, with its wide range of skincare products for all ages; Benzac and Differin OTC for mild-to-moderate acne; and Loceryl, used to treat fungal nail infections. The company operates globally with research and development centers and manufacturing sites throughout the Asia Pacific, Europe, the Middle East, Africa, and North & Latin America. For more information, Inquire Now! Related Reports: Drug Discovery Services Market Injectable Drug Delivery Market Pharmaceutical Drug Delivery Market Artificial Intelligence in Drug Discovery Market Pharmaceutical Contract Manufacturing Market Get access to the latest updates on Topical Drug Delivery Companies and Topical Drug Delivery Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
